Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies
if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the
same subfield and year (this is the minimum needed to enter the top 1%, not the average
within it), or reaches the top citation threshold in at least one of its specific research
topics.
High-performance medicine: the convergence of human and artificial intelligence
Coronary morphologic and clinical determinants of procedural outcome with angioplasty for multivessel coronary disease. Implications for patient selection. Multivessel Angioplasty Prognosis Study Group.
19901.1k citationsEric J. Topol et al.Circulationprofile →
A comparison of deep learning performance against health-care professionals in detecting diseases from medical imaging: a systematic review and meta-analysis
Effect of stromal-cell-derived factor 1 on stem-cell homing and tissue regeneration in ischaemic cardiomyopathy
20031.0k citationsStephen G. Ellis, Eric J. Topol et al.The Lancetprofile →
Predictors of 30-Day Mortality in the Era of Reperfusion for Acute Myocardial Infarction
1995877 citationsEric J. Topol, Amadeo Betriu et al.Circulationprofile →
Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
The personal and clinical utility of polygenic risk scores
2018863 citationsAli Torkamani, Eric J. Topol et al.profile →
Cardiac Troponin T Levels for Risk Stratification in Acute Myocardial Ischemia
1996859 citationsChristopher B. Granger, Robert M. Califf et al.New England Journal of Medicineprofile →
Bivalirudin and Provisional Glycoprotein IIb/IIIa Blockade Compared With Heparin and Planned Glycoprotein IIb/IIIa Blockade During Percutaneous Coronary Intervention
2003836 citationsA. Michael Lincoff, John A. Bittl et al.profile →
Aortocoronary Saphenous Vein Graft Disease
1998836 citationsEric J. Topol et al.Circulationprofile →
State of Telehealth
2016800 citationsEric J. Topol et al.New England Journal of Medicineprofile →
Prognostic Value of Myeloperoxidase in Patients with Chest Pain
2003796 citationsEric J. Topol et al.New England Journal of Medicineprofile →
A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease
2003786 citationsPatricia A. Gum, Kandice Kottke‐Marchant et al.profile →
Effect of Antihypertensive Agents on Cardiovascular Events in Patients With Coronary Disease and Normal Blood Pressure
Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months
1994636 citationsEric J. Topol, Stephen G. Ellis et al.The Lancetprofile →
Profile and prevalence of aspirin resistance in patients with cardiovascular disease
2001633 citationsPatricia A. Gum, Kandice Kottke‐Marchant et al.The American Journal of Cardiologyprofile →
Recognition of the Importance of Embolization in Atherosclerotic Vascular Disease
2000601 citationsEric J. Topol et al.Circulationprofile →
Applications of digital technology in COVID-19 pandemic planning and response
This map shows the geographic impact of Eric J. Topol's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eric J. Topol with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eric J. Topol more than expected).
This network shows the impact of papers produced by Eric J. Topol. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eric J. Topol. The network helps show where Eric J. Topol may publish in the future.
Co-authorship network of co-authors of Eric J. Topol
This figure shows the co-authorship network connecting the top 25 collaborators of Eric J. Topol.
A scholar is included among the top collaborators of Eric J. Topol based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Eric J. Topol. Eric J. Topol is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
Davis, Hannah, Lisa McCorkell, Julia Moore Vogel, & Eric J. Topol. (2023). Long COVID: major findings, mechanisms and recommendations. Nature Reviews Microbiology. 21(3). 133–146.2078 indexed citations breakdown →
5.
Moor, Michael, Oishi Banerjee, Zahra Shakeri Hossein Abad, et al.. (2023). Foundation models for generalist medical artificial intelligence. Nature. 616(7956). 259–265.738 indexed citations breakdown →
6.
Meskó, Bertalan & Eric J. Topol. (2023). The imperative for regulatory oversight of large language models (or generative AI) in healthcare. npj Digital Medicine. 6(1). 120–120.519 indexed citations breakdown →
7.
Muse, Evan D., Ali Torkamani, & Eric J. Topol. (2018). When genomics goes digital. The Lancet. 391(10138). 2405–2405.3 indexed citations
Fuster, Valentı́n, Eric J. Topol, & Elizabeth G. Nabel. (2005). Atherothrombosis and coronary artery disease. Lippincott Williams & Wilkins eBooks.51 indexed citations
11.
Rajagopal, N.A., A. Michael Lincoff, Hitinder S. Gurm, et al.. (2004). Outcomes of patients with acute coronary syndromes who are treated with bivalirudin during PCI: An analysis from the REPLACE-2 trial. Circulation. 110(17). 340–340.34 indexed citations
12.
Califf, RM, RA Harrington, Marc Vallée, et al.. (2003). Higher Aspirin Dose is Associated with Reduced Mortality and More Serious Bleeding in Patients with Recent Cerebrovascular or Coronary Ischemic Events: Insights from the BRAVO Trial. Circulation. 108(17).1 indexed citations
Hasdai, David, Eric J. Topol, Rakhi Kilaru, et al.. (2001). Frequency, Patient Characteristics, and Outcomes of Mild to Moderate Heart Failure Complicating ST-Segment Elevation Acute Myocardial Infarction: Lessons from Four International Fibrinolytic Therapy Trials. Circulation. 104(17).1 indexed citations
16.
Gum, Patricia A., Kandice Kottke‐Marchant, Emilio Poggio, et al.. (2001). Profile and prevalence of aspirin resistance in patients with cardiovascular disease. The American Journal of Cardiology. 88(3). 230–235.633 indexed citations breakdown →
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.